Go to the list of all blogs
Joma Foster's Avatar
published in Blogs
Apr 20, 2026

MDA Space Ltd. (MDA): Record Q4 Growth and NYSE Debut Fuel +80% YTD Gains

```html

Key Takeaways

  • MDA Space Ltd. reported record Q4 2025 revenue growth of 44%, boosting investor confidence.
  • Successful NYSE debut via $300 million IPO enhanced U.S. visibility and liquidity.
  • J.P. Morgan forecasted 25% share price upside by year-end, citing strong fundamentals.
  • Year-to-date gains exceed 80%, reflecting robust space sector demand.
  • Upcoming Q1 2026 earnings call on May 7 to provide further guidance.
  • Substantial backlog supports multi-year revenue visibility.

Current Market Snapshot

From what I see, MDA Space Ltd. (MDA) has shown real resilience and upward momentum in recent weeks, amid growing interest in space technology. The stock is trading near multi-month highs with increased volume, supported by its expanded U.S. presence and solid fundamentals. Broader market cycles favoring aerospace and defense have added to the positive sentiment, as investors position for growth in satellite systems and robotics. Volatility has stayed moderate, with shares reflecting optimism around operational execution and industry tailwinds. I also checked this using Tickeron’s AI Screener to compare MDA against peers.

Recent Developments Driving MDA Price Action

I've been following MDA Space Ltd., a leader in space robotics, satellite systems, and geospatial intelligence, as its stock has advanced significantly in recent sessions. Key milestones and positive analyst feedback have been the main drivers. The company's NYSE debut on March 12, 2026, through a US$300 million IPO was pivotal—it expanded access to U.S. investors, boosted liquidity, and underscored MDA's role in the space economy, leading to sustained buying.

Earlier in March, record Q4 2025 results—44% revenue growth to a quarterly high and net profit of $24 million—continued to support this strength. These numbers validated MDA's emphasis on high-margin contracts in satellite constellations and robotics, with a growing backlog offering clear revenue visibility. Shares moved toward analyst targets around CA$54, with market cap approaching CA$6.6 billion.

On April 6, J.P. Morgan started coverage with a bullish view, forecasting 25% upside to year-end based on execution in key programs and U.S. government contracts. This, along with consensus targets averaging CA$48 (highs to CA$57), drove further gains—shares traded above CA$48 on higher volume. Macro trends like demand for space infrastructure amid geopolitical tensions and satellite expansions have helped. The April 14 announcement of the Q1 2026 earnings call and shareholder meeting on May 7 has built anticipation for backlog updates and new contracts. Overall, these factors highlight MDA's edge in lunar robotics and Earth observation, even as TSX aerospace peers have lagged.

Trending AI Robots

One resource I rely on for ideas in volatile markets like this is Tickeron’s AI Trading Bots, specifically their Trending AI Robots page. It curates top performers from a library of 351 bots trading thousands of tickers across sectors. Selected algorithmically for adapting to current conditions, they show annualized returns from +15% to over +123%, win rates of 54% to 88%, and profit factors up to 11.4. Styles range from short-term signal agents on 5-minute charts to trend-following agents with risk management over days to weeks, and multi-ticker strategies in aerospace, semiconductors, and ETFs. For example, bots targeting defense and space tickers like ITA (aerospace ETF), RKLB, and KTOS have profit-to-drawdown ratios over 20 in some cases. It's worth checking for copy trading that fits space sector plays like MDA.

2026 Outlook and Key Factors to Monitor

Looking ahead to 2026 for MDA Space Ltd., I'm watching execution on its substantial backlog, especially large satellite constellation projects and robotics for lunar and defense uses. Strong demand in geospatial services and U.S. government partnerships, boosted by the NYSE listing, set the stage for revenue acceleration. Trends like proliferated LEO networks and space sustainability create opportunities, though complex contract risks persist.

Key items include Q1 earnings guidance on May 7 for backlog progress and margins. I'll track competitive pressures, supply chain issues for components, and regulatory changes in export controls. Cost control during R&D, plus macro factors like interest rates on capital projects, will matter. Against chances in space tourism and Earth observation analytics, MDA's backlog-to-cash conversion will drive long-term value. This is important because it ties directly to sustained growth.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

```
Related Ticker: MDA

MDA in +5.04% Uptrend, growing for three consecutive days on September 17, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where MDA advanced for three days, in 175 of 208 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where MDA's RSI Indicator exited the oversold zone, 17 of 23 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

The Aroon Indicator entered an Uptrend today. In 166 of 222 cases where MDA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 75%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MDA as a result. In 47 of 67 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 70%.

The Moving Average Convergence Divergence Histogram (MACD) for MDA turned negative on October 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 28 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 65%.

MDA moved below its 50-day moving average on September 28, 2026 date and that indicates a change from an upward trend to a downward trend.

The 50-day moving average for MDA moved below the 200-day moving average on September 30, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MDA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 68%.

MDA broke above its upper Bollinger Band on September 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 34 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 52 (best 1 - 100 worst), indicating steady price growth. MDA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 53 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.769) is normal, around the industry mean (6.305). P/E Ratio (55.638) is within average values for comparable stocks, (58.116). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.564). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (2.913) is also within normal values, averaging (18.330).

The Tickeron Profit vs. Risk Rating rating for this company is 54 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 76, placing this stock slightly better than average.

The Tickeron SMR rating for this company is 80 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

Notable companies

The most notable companies in this group are GE Aerospace (NYSE:GE), Boeing Company (NYSE:BA), Lockheed Martin Corp (NYSE:LMT), Northrop Grumman Corp (NYSE:NOC), Virgin Galactic Holdings (NYSE:SPCE).

Industry description

Aerospace & Defense is one of largest industries in the U.S., mainly comprising the following areas: commercial airliners, military aircraft, missiles, space, and general aviation. Focused heavily on research & development, it is also one of the fastest growing industries. Military aircraft has the largest market share in the industry’s sales, followed by space systems, civil aircraft, and missiles. Aerospace exports, directly and indirectly, support more jobs than the export of any other commodity, according to a study by the U.S. Department of Commerce. Boeing Company, Lockheed Martin Corporation and General Electric Company are some of the most prominent players in this space.

Market Cap

The average market capitalization across the Aerospace & Defense Industry is 38.94B. The market cap for tickers in the group ranges from 4.49 to 1.92T. SPCX holds the highest valuation in this group at 1.92T. The lowest valued company is BDRPF at 4.49.

High and low price notable news

The average weekly price growth across all stocks in the Aerospace & Defense Industry was -1%. For the same Industry, the average monthly price growth was -8%, and the average quarterly price growth was -11%. SPCX experienced the highest price growth at 18%, while PUSA experienced the biggest fall at -21%.

Volume

The average weekly volume growth across all stocks in the Aerospace & Defense Industry was 19%. For the same stocks of the Industry, the average monthly volume growth was 41% and the average quarterly volume growth was -24%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 45
P/E Growth Rating: 70
Price Growth Rating: 62
SMR Rating: 77
Profit Risk Rating: 76
Seasonality Score: 14 (-100 ... +100)
View a ticker or compare two or three
MDA
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry AerospaceDefense

Industry
Telecommunications Equipment
Address
7500 Financial Drive
Phone
+1 905 790-2800
Employees
4000
Web
https://www.mda.space
Interact to see
Advertisement
UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studio—a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
ARM stock surged +26% over the past 30 days, driven by announcements of in-house chip production and strong analyst upgrades amid AI enthusiasm. Over the past quarter, the stock climbed +38%, reflecting robust Q3 earnings beat with 26% revenue growth and data center royalty doubling.
Sable Offshore Corp. (SOC) is an independent oil and gas company focused on offshore operations in federal waters off California. The company owns and operates three platforms in the Santa Ynez Unit (SYU), spanning 16 federal leases across approximately 76,000 acres, along with subsea pipelines for crude oil, natural gas, and produced water transport to onshore facilities. Its core business model centers on restarting and developing prolific fields like the SYU, which had been idle due to regulatory and legal hurdles following a 2015 pipeline spill.
As a provider of onshore drilling and completion services, Patterson-UTI Energy (PTEN) is gearing up for a key Q1 2026 earnings report against the backdrop of fluctuating oil prices and steady U.S. rig demand. The company's integrated approach across Drilling Services, Completion Services, and Drilling Products gives it a solid footing in North American shale plays. In my view, recent quarters like Q4 2025, where revenue exceeded estimates despite a net loss, highlight its resilience. This upcoming report will offer insights into activity levels, margin trends, and capital discipline amid supply growth and geopolitical tensions. With strong free cash flow and recent dividend increases, PTEN's focus on shareholders stands out, making this a critical gauge for the 2026 outlook in the cyclical oilfield services sector.
When geopolitical turmoil sends markets into chaos, most retail traders freeze — but Tickeron's Energy (OXY, EOG, DVN, FANG, APA, MTDR) AI Trading Agent is built to thrive in exactly these conditions. This 15-minute and 60-minute AI-powered robot has delivered a +76.22% annualized return with a 64.21% win rate and a Profit Factor of 2.70 — trading six of the most volatile and opportunity-rich energy tickers on the market.
The global energy sector is on fire — literally and figuratively. With crude oil prices swinging 20–30% in response to geopolitical flashpoints, OPEC+ production cuts, and escalating conflicts in Eastern Europe and the Middle East, traders who aren't using AI-powered tools are flying blind. Enter Tickeron's Energy (Oil & Gas – E&P) AI Trading Agent — a 60-minute signal robot built exclusively around five high-impact Exploration & Production tickers, now posting a staggering +49% Annualized Return and +1,251% 30-Day Annualized Return, with $14,703 in closed-trade P&L on a $30,000 simulated balance.
From what I see, Cheniere Energy Partners (CQP) holds a commanding position through its ownership and operation of the Sabine Pass LNG terminal in Louisiana, the largest LNG production facility in the U.S. with approximately 30 million tonnes per annum (mtpa) capacity across six trains, alongside the connected Creole Trail Pipeline. This setup makes CQP a leader in U.S. LNG exports, which have accounted for about 11% of global supply in recent years. The company's ~80% contracted production through long-term sale and purchase agreements (SPAs) provides revenue stability, with weighted average remaining lives of around 13 years.
In my view, Regeneron Pharmaceuticals holds a strong leadership position in biotechnology, thanks to its proprietary VelociSuite technologies, including VelocImmune for fully human antibody discovery. This enables a robust pipeline across immunology, oncology, ophthalmology, and rare diseases. The company's integrated model—from discovery to commercialization—drives high R&D productivity, with approximately 45 clinical programs and key partnerships like Sanofi for Dupixent and Bayer for EYLEA.
As I review argenx SE's place in the market, its strong footing in immunology stands out. This commercial-stage biopharmaceutical company focuses on differentiated antibody therapies for severe autoimmune diseases. The flagship product, VYVGART (efgartigimod), a first-in-class neonatal Fc receptor (FcRn) inhibitor, has secured leadership in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), with approvals across the U.S., Europe, and Japan. The Immunology Innovation Program (IIP) fuels a robust pipeline, featuring next-generation FcRn candidates like ARGX-213 and ARGX-124, alongside first-in-class assets such as empasiprubart (C2 inhibitor, ARGX-117) and adimanebart (MuSK agonist).
I've long admired Alnylam Pharmaceuticals as the pioneer in RNA interference (RNAi) therapeutics, a gene-silencing technology that has delivered six approved products, including AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran). The company's proprietary platform, enhanced by GalNAc conjugation for liver targeting and emerging extra-hepatic delivery innovations, creates a solid competitive moat in precision genetic medicines.
As I review BeOne Medicines AG's position in the oncology space, what stands out is its role as a global leader with a diversified portfolio that includes both commercial-stage therapies and a deep pipeline targeting hematologic and solid tumors. The flagship product, BRUKINSA (zanubrutinib), a Bruton's Tyrosine Kinase (BTK) inhibitor, has secured approvals in over 75 markets, solidifying its dominance in chronic lymphocytic leukemia (CLL) and other blood cancers. This is complemented by TEVIMBRA (tislelizumab), an anti-PD-1 antibody approved in more than 50 markets for various indications, which broadens its reach in immunotherapy.
Rio Tinto holds a premier position as one of the world's largest mining companies, anchored by low-cost, Tier 1 assets. Its Pilbara iron ore operations in Australia deliver industry-leading margins, thanks to integrated rail and port infrastructure that gives it a structural cost advantage over higher-cost producers. In copper, the company has significant stakes in Escondida, the world's largest copper mine, and full ownership of Oyu Tolgoi in Mongolia, setting it up well to benefit from tightening supply as demand surges for electrification and renewables.
I've always been impressed by how Visa (V) commands the global payments landscape. As an open-loop network, it connects issuers, acquirers, merchants, and consumers without issuing cards or extending credit itself. The VisaNet platform processes over 65,000 transactions per second across more than 200 countries, supporting a ~52% share of the global credit card market and ~60% of debit. This scale generates powerful network effects, where greater adoption benefits everyone involved and creates formidable barriers to entry.